Michael Hufford, currently co-founder and CEO of both LyGenesis, Inc., an organ regeneration biotech, and Harm Reduction Therapeutics, Inc., a company working to bring the opioid overdose drug naloxone over the counter, set out initially on an academic track. Hufford received a master’s degree and PhD in clinical psychology from the University of Pittsburgh, before becoming a clinical research fellow in the department of psychiatry at Harvard’s McLean Hospital. At McLean, Hufford had the opportunity to “dive into the deep end of the pool” of severe psychiatric comorbidities and saw first-hand how many patients were “falling through the cracks of our ability to care for them as a society.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
